January 2025 in “Plastic Surgery and Reconstructive Medicine” Plasmatherapy improves immune status in vitiligo patients, especially those with segmental vitiligo.
April 2023 in “Journal of Investigative Dermatology” Interface dermatitis is the most common skin change in drug-induced hypersensitivity syndrome.
June 2023 in “Research Square (Research Square)” Hair loss in male pattern baldness is linked to changes in immune cell behavior around hair follicles.
November 2025 in “Indian Journal of Nephrology” Hair dye may trigger anti-GBM disease relapse, and rituximab can help manage it.
46 citations
,
October 2018 in “JCI insight” CD8+ T cells are involved in alopecia areata and may cause disease relapse.
April 2023 in “Journal of Investigative Dermatology” IL-9/IL-9R signaling can negatively affect human hair growth and may be a target for treating hair loss conditions.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Intravenous methylprednisolone helped over half of alopecia areata patients regrow hair, but many relapsed.
March 2025 in “JAAD International” Alopecia areata is rare in organ transplant patients and may be linked to the drug tacrolimus.
27 citations
,
March 2018 in “Allergy and asthma proceedings” People with alopecia areata often have higher rates of allergies and autoimmune diseases.
June 2020 in “Annals of the Rheumatic Diseases” Patients with Systemic Sclerosis have much higher levels of GDF-15, which could help predict organ involvement and guide treatment.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
19 citations
,
September 2008 in “Journal of Cellular Physiology” Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.
107 citations
,
July 1991 in “Journal of Allergy and Clinical Immunology”
Many patients in the rheumatology clinic adjusted or stopped their medications due to side effects.
4 citations
,
January 2009 in “Indian Journal of Dermatology, Venereology and Leprology” A patient with granuloma annulare experienced both isotopic and isomorphic responses, with skin lesions responding to steroids but relapsing after stopping treatment.
September 2025 in “Radboud University Press eBooks” AHR ligands could treat inflammatory skin diseases.
1 citations
,
October 2024 in “QJM” IL-12/23 inhibitors are more effective and have fewer common side effects than anti-TNF alpha for treating psoriasis.
3 citations
,
August 2024 in “Frontiers in Immunology” Targeting specific biomarkers and immune signals is more effective and safer for treating inflammatory skin diseases.
18 citations
,
September 2022 in “Cold Spring Harbor Perspectives in Biology” Controlling immune responses with biomaterials can reduce scarring and improve skin regeneration.
20 citations
,
September 2003 in “Journal of Investigative Dermatology” Targeting MIG and MCP-1 may help treat inflammation in alopecia areata.
CMV infection increases the risk of GvHD after bone marrow transplants.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
15 citations
,
January 2024 in “The AAPS Journal” 50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
6 citations
,
June 2023 in “Journal of the European Academy of Dermatology and Venereology” Inflammation damages sweat ducts, causing sweat gland injury.
August 2020 in “Benha Journal of Applied Sciences” Higher NLR, PLR, and MPV may help diagnose androgenetic alopecia.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
July 2023 in “Photodermatology, Photoimmunology and Photomedicine” Infrared radiation can cause skin aging and cancer at high temperatures but may have therapeutic benefits at controlled levels.
Alopecia areata involves immune system changes, especially in severe cases, with potential new treatment targets identified.